
$D D^{*} N C D^{3} D^{0} D^{*} D^{2} N N D^{1/2} D^{1/2} D_{2} D^{0} D^{3/4} D^{2} D^{3/4} D^{2} D^{1/2} D^{1$

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8458099/publications.pdf

Version: 2024-02-01



| # | Article | IF | CITATIONS |
|---|--|------|-----------|
| 1 | OP0187â€RITUXIMAB AND CYCLOPHOSPHAMIDE COMPARISON FOR EFFICACY AND SAFETY IN THE PATIENTS WITH SYSTEMIC SCLEROSIS ASSOCIATED WITH INTERSTITIAL LUNG DISEASE. , 2019, , . | | 3 |
| 2 | Anti-topoisomerase 1 antibody level changes after B Ñ e ll depletion therapy in systemic sclerosis. Nauchno-Prakticheskaya Revmatologiya, 2022, 60, 57-63. | 1.0 | 3 |
| 3 | AB0218â€CORRELATION BETWEEN IMMUNOLOGICAL PARAMETERS AND PULMONARY FUNCTION PARAMETER IN THE PATIENTS WITH SSC AND ILD OVER 5 YEARFOLLOW UP STUDY. , 2019, , . | S | 2 |
| 4 | Autologous hematopoietic stem cell transplantation in the treatment of systemic sclerosis. Part 2. Safety and complications. Sovremennaya Revmatologiya, 2021, 15, 66-72. | 0.5 | 1 |
| 5 | Short-term absolute B-cell counts monitoring in systemic sclerosis patients treated with rituximab. Nauchno-Prakticheskaya Revmatologiya, 2020, 58, 395-400. | 1.0 | 1 |
| 6 | THU0337â€COMPARISON OF THE EFFICACY OF TWO RITUXIMAB REGIMENS IN THE PATIENTS WITH SYSTEMIC SCLEROSIS ASSOCIATED WITH INTERSTITIAL LUNG DISEASE. , 2019, , . | | 0 |
| 7 | SAT0274â€THE EFFECT OF RITUXIMAB ON LUNG FUNCTION AND SKIN SCORE IN SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE. LONG-TERM OBSERVATION. , 2019, , . | | 0 |
| 8 | AB0651â€THE INFLUENCE OF RITUXIMAB THERAPY ON THE DYNAMICS OF THE BASIC PARAMETERS AND ACTIN OF SYSTEMIC SCLEROSIS. , 2019, , . | /ITY | 0 |
| 9 | AB0217â€ASSOCIATION OF EUROPEAN SCLERODERMA STUDY GROUP ACTIVITY INDEX (ESCSG-AI) WITH PROGRESSION PULMONARY ALTERATIONS BY HRCT IN PATIENTSWITH SYSTEMIC SCLEROSIS OVER A FIVE YEAR PERIOD. , 2019, , . | | 0 |